Adaptimmune Therapeutics plc (ADAP) Financial Statements (2024 and earlier)

Company Profile

Business Address 60 JUBILEE AVENUE
ABINGDON, OXFORDSHIRE, OX14 4RX
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments204,707165,554204,605199,670258,089304,218
Cash and cash equivalents76,969119,866108,03379,00197,81189,539
Short-term investments127,73845,68896,572120,669160,278214,679
Receivables3,0622,0707,92553,53449,42542,888
Prepaid expense13,0406,7879,4728,05210,45010,077
Other current assets1,7651,6641,9271,7121,8742,103
Other undisclosed current assets39,19737,67331,4411,1711,327175
Total current assets:261,771213,748255,370264,139321,165359,461
Noncurrent Assets
Operating lease, right-of-use asset22,02717,94718,01917,60719,38021,145
Property, plant and equipment55,49254,36553,51648,17645,40036,689
Intangible assets, net (including goodwill)463443442568612788
Intangible assets, net (excluding goodwill)463443442568612788
Restricted cash and investments3,2311,5781,5691,7121,7131,716
Total noncurrent assets:81,21374,33373,54668,06367,10560,338
TOTAL ASSETS:342,984288,081328,916332,202388,270419,799
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities39,95538,39735,96853,34056,65038,644
Employee-related liabilities10,3568,043
Accounts payable14,7135,1874,7536,90515,9917,017
Accrued liabilities25,24233,21031,21536,07932,61631,627
Deferred revenue31,41822,30423,52020,62222,46824,772
Other undisclosed current liabilities4,7522,9305,013(7,882)(5,486)2,735
Total current liabilities:76,12563,63164,50166,08073,63266,151
Noncurrent Liabilities
Long-term debt and lease obligation:    19,92621,63523,220
Liabilities, other than long-term debt140,208140,574182,537132,859151,086167,283
Deferred revenue117,257119,251160,892132,233150,437166,613
Other liabilities1,3611,3321,296626649670
Operating lease, liability21,59019,99120,34919,92621,63523,220
Total noncurrent liabilities:140,208140,574182,537152,785172,721190,503
Total liabilities:216,333204,205247,038218,865246,353256,654
Equity
Equity, attributable to parent126,65183,87681,878113,337141,917163,145
Common stock1,8511,4071,3991,3941,3871,342
Additional paid in capital1,057,547992,520990,656985,312980,204965,227
Accumulated other comprehensive income (loss)(3,092)(1,785)(875)6,683(1,043)(9,313)
Accumulated deficit(929,655)(908,266)(909,302)(880,052)(838,631)(794,111)
Total equity:126,65183,87681,878113,337141,917163,145
TOTAL LIABILITIES AND EQUITY:342,984288,081328,916332,202388,270419,799

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues5,13047,60111,0287,0075,5383,575
Gross profit:5,13047,60111,0287,0075,5383,575
Operating expenses(50,038)(45,945)(38,270)(49,997)(49,290)(53,556)
Operating income (loss):(44,908)1,656(27,242)(42,990)(43,752)(49,981)
Nonoperating income (expense)22,656(671)(1,537)1,644(655)12
Investment income, nonoperating 22,155     
Other nonoperating income (expense)501(671)(1,537)1,644(655)12
Income (loss) from continuing operations before equity method investments, income taxes:(22,252)985(28,779)(41,346)(44,407)(49,969)
Other undisclosed income from continuing operations before income taxes1,543676523324357338
Income (loss) from continuing operations before income taxes:(20,709)1,661(28,256)(41,022)(44,050)(49,631)
Income tax expense(680)(625)(994)(399)(470)(634)
Income (loss) from continuing operations:(21,389)1,036(29,250)(41,421)(44,520)(50,265)
Loss before gain (loss) on sale of properties:(41,421)(44,520)(50,265)
Net income (loss) available to common stockholders, diluted:(21,389)1,036(29,250)(41,421)(44,520)(50,265)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net income (loss):(21,389)1,036(29,250)(41,421)(44,520)(50,265)
Comprehensive income (loss):(21,389)1,036(29,250)(41,421)(44,520)(50,265)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1,306)(910)(7,558)7,7268,2701,829
Comprehensive income (loss), net of tax, attributable to parent:(22,695)126(36,808)(33,695)(36,250)(48,436)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: